7/1/22, 6:38 PM
`
`Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine - Bausch H ...
`
`BAUSCH- Health
`
`Bausch+ Lomb Launches LUMIFV, The First And
`Only OTC Redness Relieving Eye Drop With Low(cid:173)
`Dose Brimonidine
`
`May 07, 2018
`
`Now Available at Major U.S. Retailers
`
`LAVAL, Quebec, May 7, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health
`company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX:
`VRX), today announced the launch of LUMIFY™ (brimonidine tartrate ophthalmic solution
`0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose
`brimonidine tartrate for the treatment of eye redness.
`
`"With the availability of LUMIFY, consumers now have an innovative, over-the-counter
`treatment option that can help relieve red, irritated eyes within a minute and offer up to eight
`hours of redness reduction," said Joseph C. Papa, chairman and CEO, Va leant. "LUMIFY is
`unlike other redness relievers on the market and wi ll provide consumers a new welcomed
`alternative."
`
`Eye redness is a common, non specific issue that affects millions of people. Other redness
`relievers are commonly associated with the potential side effects of rebound redness and loss
`of efficacy over time. LUMIFY works by selectively targeting redness and thereby reducing the
`potential for these side effects.
`
`In clinical trials, LUMIFY eye drops demonstrated 95% improvement at one minute with
`significant resu lts lasting up to eight hours. A recent in-home-use-study with over 300
`participants also resu lted in a 95% satisfaction rating for the product.
`
`"LUMIFY eye drops deliver a safe and effective redness re lieving OTC option that my patients
`have been asking for," said Paul Karpecki, O.D., FAAO, director of Corneal Services at Kentucky
`Eye Institute. "I am excited to introduce these new eye drops into my practice and offer my
`patients long lasting symptom re lief without the adverse effects commonly associated with
`other redness relievers."
`
`LUMIFY is available for purchase at major retai lers nationwide, including Wa lgreens, CVS, Rite
`Aid, Walmart, Target and Amazon. The bottles, available in 2.5 ml and 7.5 ml sizes, have
`suggested retai l prices of $14.99 and $25.99, respective ly.
`
`The brimonidine tartrate ophthalmic solution 0.025% product was licensed by Eye Therapies,
`Inc. to Bausch & Lomb Incorporated or its affiliates.
`
`https://ir.bauschhealth.com/news-releases/2018/05-07-2018-130249958
`
`1/3
`
`Eye Therapies Exhibit 2103, 1 of 3
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/1/22, 6:38 PM
`Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine - Bausch H ...
`For more informat ion, please visit
`www. Lu mifyEyeDrops. com
`
`About Bausch + Lomb
`Bausch + Lomb, a Va leant Pharmaceuticals Int ernational, Inc. company, is a leading global eye
`health organization that is solely focused on protecting, enhancing and restoring people's
`eyesight. Our core businesses include over-the-counter supplements, eye care products,
`ophthalmic pharmaceuticals, contact lenses, lens care products, opht halmic surgical devices
`and instruments. Bausch + Lomb develops, manufactures and markets one of t he most
`comprehensive product portfolios in the industry, which is available in more than 100 countries.
`
`About Valeant
`Va leant Pharmaceuticals International, Inc. (NYSE/ TSX: VRX) is a global company whose
`mission is to improve people's lives with our health care products. We develop, manufact ure
`and market a range of pharmaceutical, medical device and over the counter products, primarily
`in the t herapeutic areas of eye health, gast roenterology and dermatology. We are delivering on
`our commitments as we build an innovat ive company dedicated to advancing global health.
`More information can be found at
`www.valeant.com
`
`Forward-looking Statements
`This news release may contain forward- looking statements which may generally be identified
`by t he use of t he words "anticipates," "e pects," "intends," "plans," "should," "could," "would,"
`"may," "wi ll," "believes," "estimates," "potential," "target," or "continue" and variations or
`similar e pressions. These statements are based upon the current e pectations and beliefs of
`management and are subject to certain risks and uncertainties that could ca use actual resu lts
`to differ materially from those descri bed in the forward-looking statements. These risks and
`uncertaint ies include, but are not limited to, risks and uncertainties discussed in Va leant's most
`recent annual or quarterly report and detailed from time to time in Va leant's other fi lings with
`the Securities and Exchange Commission and the Canadian Securities Administrators, which
`factors are incorporated herein by reference. Readers are cautioned not to place undue re liance
`on any of these forward-looking statements. These forward-looking statements speak only as
`of the date hereof. Va leant undertakes no obligation to update any of these forward looking
`statements to reflect events or circumstances after the date of t his news release or to reflect
`actual outcomes, unless required by law.
`
`LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates.
`© 2018 Bausch & Lomb Incorporated.
`
`Investor Contact:
`
`Arthur Shannon
`
`Media Contact:
`
`Lainie Keller
`
`arthur.shannon@valeant.com
`
`lainie.keller@valeant.com
`
`https://ir.bauschhealth.com/news-releases/2018/05-07-2018-130249958
`
`2/3
`
`Eye Therapies Exhibit 2103, 2 of 3
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/1/22, 6:38 PM
`
`Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine - Bausch H ...
`
`(514) 856 3855
`
`(908) 927 0617
`
`(877) 281 -6642 (toll free)
`
`BAUSCH LOMB
`
`View original content with multimedia :
`http://www. prnewswi re. com/ news-releases/ba usch--lomb-lau nches-1 u mify-the-fi rst-a nd-on ly-o
`tc-redness-relieving-eye-drop-with-low-dose-brimonidine-300643308.html
`
`SOURCE Bausch + Lomb
`
`,f""'1,, Pawarad b_y
`'\Jl SITECORE'
`
`https://ir.bauschhealth.com/news-releases/2018/05-07-2018-130249958
`
`3/3
`
`Eye Therapies Exhibit 2103, 3 of 3
`Slayback v. Eye Therapies - IPR2022-00142
`
`